232 related articles for article (PubMed ID: 8414460)
1. [Smoldering myeloma].
Dolgos J; Patakfalvi A
Orv Hetil; 1993 Sep; 134(39):2155-7. PubMed ID: 8414460
[TBL] [Abstract][Full Text] [Related]
2. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: recognition and management.
George ED; Sadovsky R
Am Fam Physician; 1999 Apr; 59(7):1885-94. PubMed ID: 10208707
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
Gruber A; Osby E
Chemioterapia; 1987 Jun; 6(2 Suppl):725-6. PubMed ID: 3509531
[No Abstract] [Full Text] [Related]
5. IgD multiple myeloma. A report of three cases.
Martini R; Santini S; Bottari G
Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
[TBL] [Abstract][Full Text] [Related]
7. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
Franchi F; Seminara P; Rossi Fanelli F
Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
[TBL] [Abstract][Full Text] [Related]
8. [Nonproducing myeloma without evident bone lesion].
Kawatani T; Maeda N; Hosoda A; Agou H; Nakai K; Kawasaki H
Rinsho Ketsueki; 1990 Jun; 31(6):842-6. PubMed ID: 2214175
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
10. [IgD myeloma. Presentation of a case and review of the literature].
Fiore G; Baraldi A; Cremonte LG; Marenco M
Minerva Med; 1990; 81(1-2):103-5. PubMed ID: 2314611
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: diagnosis and treatment.
Nau KC; Lewis WD
Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
[TBL] [Abstract][Full Text] [Related]
12. [Rapid growth of glioblastoma during therapy for multiple myeloma: case report].
Sonoda Y; Kumabe T; Umezawa K; Shimizu H; Murakawa Y; Kanamaru R; Yoshimoto T
No Shinkei Geka; 1998 Aug; 26(8):737-41. PubMed ID: 9744004
[TBL] [Abstract][Full Text] [Related]
13. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma.
Hayes MJ; Carey JL; Krauss JC; Hedstrom DL; Gulbranson RL; Keren DF
Eur J Haematol; 2007 Apr; 78(4):353-7. PubMed ID: 17378894
[TBL] [Abstract][Full Text] [Related]
14. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
15. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment.
Carlson K; Aström G; Nyman R; Ahlström H; Simonsson B
Acta Radiol; 1995 Jan; 36(1):9-14. PubMed ID: 7833177
[TBL] [Abstract][Full Text] [Related]
16. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
17. Improved outcome in solitary bone plasmacytomata with combined therapy.
Avilés A; Huerta-Guzmán J; Delgado S; Fernández A; Díaz-Maqueo JC
Hematol Oncol; 1996 Sep; 14(3):111-7. PubMed ID: 9119355
[TBL] [Abstract][Full Text] [Related]
18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
19. Primary systemic amyloidosis with delayed progression to multiple myeloma.
Rajkumar SV; Gertz MA; Kyle RA
Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
[TBL] [Abstract][Full Text] [Related]
20. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
Hájek R; Adam Z; Vásová I; Král Z
Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
